Literature DB >> 33420814

A risk factor analysis of complications after surgery for vulvar cancer.

Georgios Gitas1, L Proppe2, S Baum2, M Kruggel2, A Rody2, D Tsolakidis3, D Zouzoulas3, A S Laganà4, V Guenther5, D Freytag5, I Alkatout5.   

Abstract

INTRODUCTION: Despite the less frequent use of surgery in patients with vulvar cancer, the high rates of postoperative complications are still a matter of concern. The aim of the present study was to identify risk factors that influence postoperative complications rates in vulvar cancer and identify specific clinical parameters that may influence their incidence. MATERIALS: Patients who underwent curative-intent surgery for squamous cell carcinoma of the vulva from 2003 to 2018 were selected. All patient characteristics were analyzed as risk factors for the development of postoperative lymphocele, lymphedema, and wound dehiscence. The patients were followed up for 2 years postoperatively.
RESULTS: The investigation comprised 121 patients, of whom 18.1% developed wound dehiscence, 17.7% a lymphocele, and 20.4% lymphedema. We found no significant evidence of an association between patient's characteristics and postoperative complications. The depth of tumor invasion and the appearance of lymph-node metastasis were significantly associated with postoperative complications. Free resection margins of 5 mm or more were associated with a reduced risk of postoperative complications compared to resection margins less than 5 mm. No complications were encountered after sentinel node biopsy (SNB). Complication rates were associated with inguinofemoral lymphadenectomy, but not with the extent of lymphadenectomy. The development of a lymphocele or wound dehiscence may be correlated with the development of long-term lymphedema.
CONCLUSION: FIGO stage at diagnosis influences the risk of postoperative complications. The use of SNB minimized postoperative complications. Correlations between the free microscopic resection margin distance and the risk of postoperative wound dehiscence must be investigated further.
© 2021. The Author(s).

Entities:  

Keywords:  Lymphedema; Postoperative complications; Resection margin; Vulvar cancer; Wound dehiscence

Year:  2021        PMID: 33420814     DOI: 10.1007/s00404-020-05949-w

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  3 in total

1.  Quality of life in women with gynecologic cancer in Turkey.

Authors:  A Goker; T Guvenal; E Yanikkerem; A Turhan; F M Koyuncu
Journal:  Asian Pac J Cancer Prev       Date:  2011

2.  Carcinoma of the vulva: analysis of treatment and survival.

Authors:  K C Podratz; R E Symmonds; W F Taylor; T J Williams
Journal:  Obstet Gynecol       Date:  1983-01       Impact factor: 7.661

3.  Radical vulvectomy and bilateral inguinal lymphadenectomy through separate groin incisions.

Authors:  N F Hacker; R S Leuchter; J S Berek; T W Castaldo; L D Lagasse
Journal:  Obstet Gynecol       Date:  1981-11       Impact factor: 7.661

  3 in total
  3 in total

Review 1.  Management of Early-Stage Vulvar Cancer.

Authors:  Priscila Grecca Pedrão; Yasmin Medeiros Guimarães; Luani Rezende Godoy; Júlio César Possati-Resende; Adriane Cristina Bovo; Carlos Eduardo Mattos Cunha Andrade; Adhemar Longatto-Filho; Ricardo Dos Reis
Journal:  Cancers (Basel)       Date:  2022-08-29       Impact factor: 6.575

2.  Temporal Changes in Subcutaneous Fibrosis in Patients with Lower Extremity Lymphedema Following Surgery for Gynecologic Cancer: A Computed Tomography-Based Quantitative Analysis.

Authors:  Soyoung Lee; Dong Gyu Lee; Kyoung Tae Kim
Journal:  Diagnostics (Basel)       Date:  2022-08-12

3.  Human amniotic membrane for myocutaneous dehiscence after a radical surgical treatment of vulvar cancer: A case report.

Authors:  Stefano Restaino; Federico Paparcura; Cristina Giorgiutti; Diletta Trojan; Giulia Montagner; Giancarlo Pengo; Grazia Pividore; Roberta Albanese; Emanuele Rampino; Teresa Dogareschi; Tiziana Bove; Francesca Titone; Marco Trovò; Giorgia Garganese; Pier Camillo Parodi; Giovanni Scambia; Lorenza Driul; Giuseppe Vizzielli
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.